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ABSTRACT
Background: Duration of drug therapy is a key measure of
drug effectiveness in schizophrenia. The Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) trial
found that only olanzapine achieved a longer time to all-
cause-discontinuation (TTAD) than a standard therapy
comparator. This study compares the TTAD achieved when
using alternative antipsychotics to treat patients with schizo-
phrenia in real-world practice settings.
Methods: A total of 219,504 episodes of antipsychotic
therapy initiated in the years 2000 to 2002 were identiﬁed
using data from the California Medicaid (Medi-Cal)
program. To capture the full range of treatment scenarios
facing clinicians, four episode types were included: restarting
therapy using the drug used in the preceding episode; restart-
ing therapy using a different medication (delayed switches);
switching therapy without a break in therapy; and augmen-
tation. TTAD and changes in therapy were analyzed using
ordinary least squares and logistic regressions and Cox pro-
portional hazards models.
Results: Atypical antipsychotics consistently achieved longer
TTAD and reduced switching rates relative to conventional
antipsychotics. Differences in TTAD favoring atypical antip-
sychotics were 13 to 15 days in restart episodes; 28 to
36 days for delayed switching episodes; 41 to 52 days in
switching episodes; and 59 to 63 days for augmentation
(P < 0.0001 for all estimates). Differences between the atypi-
cal antipsychotics were smaller than reported in other studies
and may not be clinically signiﬁcant.
Conclusions: This study conﬁrms two results from the
CATIE study: Patients with schizophrenia frequently do not
achieve stable, long-term drug therapy regardless of the spe-
ciﬁc drug used, and olanzapine achieved longer TTAD
than conventional drugs. However, this study also found
that patients treated with risperidone and quetiapine also
achieved longer TTAD than patients treated with conven-
tional antipsychotics.
Keywords: antipsychotic drugs, duration of therapy,
switching.
Background
The use of atypical antipsychotics is coming under
increased scrutiny as the cost for these medications has
stressed the budgets of health systems, especially state
Medicaid programs [1]. In response, the National
Institute of Mental Health funded the Clinical Antip-
sychotic Trials of Intervention Effectiveness (CATIE)
study, which implemented a hybrid study design that
combined random assignment to alternative antipsy-
chotics while attempting to mimic real-world practice.
To date, the CATIE trial has reported three results of
particular relevance to clinical practice [2–6]. First, the
proportion of patients with 18 months of continuous
therapy was unacceptably low, ranging from 18%
for quetiapine to 36% for olanzapine. Second, only
olanzapine achieved a signiﬁcantly longer time-to-all-
cause discontinuation than perphenazine, the conven-
tional antipsychotic used as the comparison. Third,
patients switching to olanzapine and risperidone in
phase II of CATIE were found to achieve longer dura-
tion of therapy relative to quetiapine and ziprasidone.
The median duration of therapy in phase I was
9.2 months for olanzapine; 5.6 months for perphena-
zine; 4.8 months for risperidone; and 4.6 months for
quetiapine [2].
Several studies of patient compliance have found
results that are generally consistent with CATIE [2–4].
Rascati et al. [7] compared olanzapine (n = 1906) and
risperidone (n = 979) using Texas Medicaid data.
Patients with schizophrenia newly started on olanzap-
ine were less likely to discontinue treatment during the
ﬁrst year (8.89% vs. 14.51%, P < 0.0001) and had
more days of therapy in the ﬁrst year (248 days vs.
211 days, P < 0.0001) than risperidone patients.
Gibson et al. [8] compared patients with schizophrenia
using Michigan Medicaid data from 1996 to 1997.
Patients initiating treatment with olanzapine (n = 458)
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achieved a longer average duration of therapy
(166 days) relative to risperidone patients (128 days,
n = 481). Results from a multivariate Cox propor-
tional hazards model found olanzapine patients to be
27% less likely to discontinue therapy (hazard ratio
[HR] = 0.73, P < 0.01). Compliance with haloperidol
was signiﬁcantly worse relative to both olanzapine and
risperidone. Ramsey et al. [9] evaluated Medicaid-
only patients with schizophrenia who initiated
monotherapy using olanzapine (n = 895), risperidone
(n = 479), or haloperidol (n = 302) during the ﬁrst
6 months of 1997. Olanzapine patients achieved
longer duration of treatment than patients treated with
either haloperidol (+69 days) or risperidone (+29 days,
P < 0.0001 for both estimates). Using data from the
Indiana Medicaid program, Zhao et al. [10] found
signiﬁcantly longer duration of therapy for olanzapine
patients relative to both risperidone (+13 days) and
quetiapine (+18 days, P < 0.01 for both estimates).
Swartz et al. [11] compared olanzapine (n = 465), ris-
peridone (n = 350), quetiapine (n = 178), and ziprasi-
done (n = 25) with oral conventional antipsychotics
(n = 534) using data from the United States Schizo-
phrenia Care and Assessment Program (US-SCAP)
study. Unadjusted mean times to all-cause discon-
tinuation were 303 days for clozapine, 266 days for
olanzapine, 244 days for risperidone, 232 days for
quetiapine, 216 days for ziprasidone, 218 for per-
phenazine, and 179 days for combination therapy of
haloperidol and anticholinergic medications. These
relative differences were conﬁrmed by Cox propor-
tional hazards models. Finally, Haro et al. [12]
reported the 24 months results for monotherapy
patients included in the Pan-European Schizophrenia
Outpatient Health Outcomes Study. Fewer patients
treated with olanzapine discontinued therapy at
2 years (23%, n = 3701) compared with risperidone
(33%, n = 1362), quetiapine (49%, n = 545), or
typical antipsychotics (44%, n = 499).
The antipsychotic treatment episodes included in
the CATIE trial and in previous studies using retro-
spective database analyses do not represent the full
range of patients who may initiate antipsychotic drug
therapy. For example, Rosenheck et al. [5] caution
their readers that the CATIE results cannot be gener-
alized to ﬁrst-episode patients, refractory patients, the
elderly, patients with unstable medical problems,
patients in nursing homes, or patients who wish to
restart therapy using a medication used previously. The
purpose of this article is to use data from the Califor-
nia Medicaid (Medi-Cal) program to investigate the
drug therapy outcomes achieved across alternative
antipsychotics under a wider range of clinical scenarios
excluded for previous research. The patient’s antipsy-
chotic drug use history and current use at the time of
treatment initiation were derived from the patient’s
prescription drug claims over a 10-year period
between 1994 and 2003. These data were then used to
deﬁne ﬁve episode types that reﬂect time off treatment,
if any, and the antipsychotic medications used during
the patient’s prior treatment attempt. These ﬁve
episode types are: the patient’s ﬁrst-observed MediCal-
funded treatment attempt; patients restarting therapy
with a medication used in their most recent treatment
attempt; patients switching therapies after a period of
no drug therapy; patients switching drugs with no
break in treatment; and patients augmenting a pre-
existing antipsychotic drug regimen. Previous research
either required extended washout periods or combined
a mix of episode types into a single sample. As patient
compliance and drug selection could vary signiﬁcantly
across episode types (drug history), analyses that
aggregate episode types into a single sample could be
biased.
This study evaluates multiple measures of drug
therapy outcomes: the likelihood of achieving 1 year
of continuous therapy, days of continuous therapy,
and the likelihood of changing therapies using pre-
scription drug claims. Several studies have established
that measures of adherence based on prescription
drug claims are highly correlated with methods com-
monly used in clinical trials. For example, Choo et al.
[13] found that pharmacy records correlated well
with pill counts in terms of cumulative exposure and
gaps in therapy over time, although neither measure
correlated well with patient adherence with the
timing of prescribed doses. Grymonpre et al. [14]
found signiﬁcant concordance between pill counts
and pharmacy data in the elderly.
Methods
Data
A 100% sample of de-identiﬁed paid claims data from
the fee-for-service portion of the Medi-Cal program
for the period 1994 to 2003 was available for this
analysis. Patients were eligible for inclusion in the
study if they had a diagnosis of schizophrenia recorded
on a paid claim (ICD-9 code 295.xx) and ﬁlled at least
one prescription for an antipsychotic medication
during the period. A limited number of additional
exclusion criteria were applied once the drug use pat-
terns of these patients were summarized into episodes
of antipsychotic drug therapy. The research protocol
was approved by the institutional review board at the
University of Southern California.
Summary prescription drug data were created for
each antipsychotic medication used by the patient over
the entire 10-year data period. These data included the
drug used, number of pills dispensed, days supply, and
the number of days between prescriptions. Data for
“days supply” were missing on a small percentage of
prescription claims (less than 5%) and were replaced
with the average days supply recorded for each
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medication, usually a value very close to 30 days given
the predominance of monthly prescriptions under
Medi-Cal.
Unit of Analysis
An episode of antipsychotic drug therapy was deﬁned
each time a patient initiated treatment using an antip-
sychotic not used previously or restarted a medication
after a break in therapy in excess of 15 days. The
15-day gap deﬁnition was selected in collaboration
with the Medi-Cal program and reﬂects the ﬁndings of
Weiden et al. [15], who used Medi-Cal data to docu-
ment that the risk of hospitalization increased signiﬁ-
cantly in patients with schizophrenia after breaks in
therapy as short as 10 days. Analysts with the Medi-
Cal program agreed with the authors that allowing for
longer gaps in therapy would risk missing the associa-
tion between rapid destabilization of noncompliant
patients with short-term breaks in therapy. Unfortu-
nately, it is not possible to test the sensitivity of our
study results to alternative gap deﬁnitions without cre-
ating a parallel data set summarizing all episodes of
antipsychotic therapy over the entire 10-year period
for all Medi-Cal patients with a diagnosis of schizo-
phrenia using an alternative gap deﬁnition.
Five types of treatment episodes were identiﬁed
using prescription drug data, four of which were
included in this analysis:
First observed episode. By deﬁnition, each patient has
one “ﬁrst” episode of antipsychotic drug therapy
recorded in the Medi-Cal paid claims ﬁle.
Restart episodes using the same medication. Restart
episodes were deﬁned if the patient was not on active
antipsychotic drug therapy of any type for at least
15 days and initiated therapy with a medication used
in their most recent prior treatment attempt. That is,
these patients are using a speciﬁc antipsychotic inter-
mittently without using any alternative products. A
break in treatment was identiﬁed whenever a gap in
drug therapy in excess of 15 days was observed based
on days supply and reﬁll dates for all antipsychotic
medications used by the patient.
Delayed switches in drug therapy. Delayed switching
episodes were deﬁned if the patient changed therapy
from the drugs used in their most recent prior treat-
ment attempt, but after a break in the use of any
antipsychotic therapy of at least 15 days.
Switching episodes. A switching episode was deﬁned if
a patient changed medication while still on active
therapy or within 15 days of terminating a previous
episode, and discontinued use of all previous medica-
tions within 60 days after starting his or her new
therapy.
Augmentation episodes. An augmentation episode
was deﬁned when a patient changed therapies without
a break in therapy and continued to purchase one or
more of their previous medications beyond 60 days.
There will be overlapping episodes of drug use for
both switching and augmentation episodes and these
patients will enter the analysis twice, but possibly for
different episode types. For example, if a patient
restarts on Drug A, then augments with Drug B, then
the patient will have a restart and augmentation
episode sharing a period of drug use. Similarly, while
restart and delayed switching episodes have no over-
lapping periods of drug use prior to treatment can still
share overlapping post-treatment periods of drug use
(i.e., a restart episode and augmentation episode for a
patient initiated within 1 year). This is not, however,
an important issue in this study of drug therapy out-
comes, which are measured as days of continuous
therapy on both the initial medication used at the start
of the episode and on all subsequent antipsychotic
medications started without a break in therapy.
The range of episode types outlined above includes
virtually all patient attempts to use antipsychotic medi-
cations. This approach includes clinical scenarios not
typically allowed into randomized clinical trials, such
as patients switching therapies without a “washout”
period and augmentation episodes. This approach also
allows the analysis to compare across alternative medi-
cations while controlling for the treatment history of
the patient. The CATIE investigators also recognized
the importance of treatment history on compliance in
their analysis of patients in phase I who were randomly
assigned back onto the antipsychotic used previously
[8]. Treatment history data are also used as indepen-
dent variables in the statistical models to control treat-
ment selection bias.
Separate analyses are conducted by episode type as
the use of alternative drugs may vary signiﬁcantly by
episode type. Episode-speciﬁc analyses provide more
complete and relevant information for clinicians who
must select between alternative therapies across a wide
range of clinical scenarios. This approach also avoids
any confounding that may occur if the frequency of use
of these medications differs across episode type and
duration of therapy and switching rates differ signiﬁ-
cantly by type of episode. Previous research either
excluded restarting, switching, and augmentation epi-
sodes or mixed episode types into a single sample, thus
creating a potential bias against medications used
more frequently in short-duration episode types.
Four additional selection criteria were applied
once all episodes of treatment initiated by the patient
over the entire 10-year data period were abstracted
from the data. First, the ﬁrst observed episode was
dropped for all patients because of truncation of the
data which prevented determination of the patient’s
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drug history at the start of treatment. For example, it
is thought that a signiﬁcant proportion of patients
with schizophrenia qualiﬁed for Medicaid coverage at
some point after their initial treatment attempt using
an antipsychotic. Therefore, ﬁrst observed episodes
are likely to be a mix of episode types and were
excluded from further analysis. Second, all episodes
were screened for a minimum of 6 months of pre-
treatment data and 1-year (12 month) post-treatment
data surrounding the month in which treatment was
initiated. Third, this study was limited to episodes of
drug therapy initiated after January 1, 2000 to insure
that the “access effects” associated with the expan-
sion of the Medi-Cal formulary in October 1997 had
stabilized [16] and to avoid early quetiapine episodes
as it received Food and Drug Administration ap-
proval in the fall of 1997. Finally, episodes of care
initiated with either ziprasidone or clozapine were
excluded from this analysis because of the limited
sample size and the late availability of ziprasidone
during the study period.
Statistical Methods
Compliance was measured as days of continuous
therapy for both the index medication used in the
treatment episode and across all medications used sub-
sequently so long as there was no gap in drug avail-
ability in excess of 15 days. Other drug therapy
outcomes include the time to the patient’s use of an
alternative antipsychotic not in use at the start of the
episode. These time-to-switch data are then used to
deﬁne dichotomous variables indicating that the
patient switched or augmented their index medication
within 1 year. Cox proportional hazards models were
estimated for the time-to-termination and time-to-
change in therapy. Logistic regression models were
estimated for dichotomous outcome variables created
if the time-to-termination or time-to-change in therapy
was less than 360 days (i.e., within 1 year). Finally,
ordinary least squares (OLS) regressions were esti-
mated for duration of uninterrupted therapy.
The presence of multiple episodes for some patients
violates the assumption of independence across obser-
vations. Under these conditions, the regression estima-
tors continue to be unbiased; however, the estimated
standard errors are biased. The heteroscedasticity-
consistent matrix estimator developed by White [17]
was used to adjust estimated standard errors for clus-
tering of episode observations by patient, using proce-
dures available in STATA [18].
Independent Variables
The development of an exhaustive list of independent
variables is the ﬁrst line of defense against treatment
selection bias in nonrandomized studies that compare
patient outcomes across alternative treatment options.
This study has developed independent variables related
to patient demographics, the diagnostic and psycho-
tropic drug proﬁle of the patient, and use of health-
care services in the 6 months before the episode’s index
date. Four prior use variables were created: three
dichotomous variables indicating the use of acute hos-
pital, psychiatric hospital, and nursing home services
in the prior 6 months and the natural log of the total
cost for all services with dates of service in the 6-month
pretreatment period. Adjustment for missing Medicare
payments were implemented based on methods used in
previous research [16].
Antipsychotic drug use history variables include
whether or not two antipsychotic medications were
ﬁrst purchased on the index date of the episode, the
duration of therapy achieved during the patient’s pre-
vious episode of therapy and the number of days
between episodes (restart and delayed switching epi-
sodes), prior use of depot formulations, a dichotomous
variable indicating whether or not the patient’s new
episode constituted a change in antipsychotic class
(i.e., using an atypical antipsychotic after a treatment
attempt with a conventional antipsychotic), and the
average number of treatment attempts per year before
the episode start date. This latter variable was created
by maintaining a running count of episodes and then
dividing this count by the total number of days of data
available before each episode. The resulting “episodes
per day” value was transformed into an annualized
value by simply multiplying by 360 days.
Results
Baseline Patient Characteristics
The data on selected baseline characteristics of the
study sample are presented in Table 1 by episode type
and index drug. Several results point out the impor-
tance of breaking down comparisons of patient out-
comes across drugs into separate analyses by episode
type. First, the distributions of episode types are quite
different across drugs. For example, olanzapine and
risperidone are used primarily by patients restarting
treatment, having used these drugs previously (61.5%
and 57.6%, respectively). Only 38.8% of quetiapine
episodes and 43.8% of episodes using typical antipsy-
chotics are restart episodes. Second, the baseline char-
acteristics of the patient sample changes signiﬁcantly
by episode type. For example, patients initiating an
episode of augmentation therapy are more likely to be
male, disabled, white, and more costly to treat in the
prior 6 months than patients restarting a drug used
previously. Aggregating different episode types into a
single analysis could result in erroneous comparisons
across drugs if episode type affects duration of therapy.
Third, the average gap between restart episodes ranges
from 56 days for quetiapine to 99 days for typical
antipsychotics, far in excess of the minimum of 15-day
gap used to deﬁne a break in therapy. The average gap
490 Chen et al.
between episodes for delayed switching episodes is
even more dramatic, ranging between 236 days for
conventional antipsychotics and 314 days for patients
switching to olanzapine. These are the types of epi-
sodes that would be sensitive to an alternative deﬁni-
tion of a break in therapy.
Descriptive Statistics: Drug Therapy Outcomes
The descriptive statistics describing the drug therapy
outcomes achieved by patients using alternative antip-
sychotic medications are presented in Table 2. The
pattern of unadjusted drug therapy outcomes across
drugs is consistent across all episode types:
1. Patients initiating episodes of therapy using atypi-
cal antipsychotics achieve longer duration of
treatment and are less likely to switch to other
antipsychotics within 1 year.
2. The unadjusted results for patients initiating
therapy using olanzapine are consistently better
than those achieved by risperidone or quetiapine
patients, although differences are small.
3. The range of unadjusted differences in duration
across all four drugs is relatively small for patients
restarting therapy on the drug used previously
(14 days). The range of differences, however,
becomes more signiﬁcant when the patient is
changing or augmenting therapy: 35 days for
delayed switching episodes, 72 days for switching
episodes, and 96 days for augmentation episodes.
These differences in the relative performance of
alternative antipsychotics by episode type further
underscore the importance of making head-to-head
comparisons by episode type.
Multivariate Results
The OLS models of duration of therapy on the index
antipsychotic are presented in Table 3 for all four
episode types. Only those independent variables that
were statistically signiﬁcant in 3 of 4 analyses are listed
because of space limitations. All three atypical antip-
sychotics were found to achieve signiﬁcantly longer
duration of therapy on the index medication for all
types of episodes, ranging from 13 to 15 days in restart
episodes to 59 to 65 days in augmentation episodes
(P < 0.0001 for all estimates).
Several additional factors were found signiﬁcantly
to affect duration of therapy using the index medica-
tion. The patient’s duration of therapy in their prior
treatment episode was positively correlated with dura-
tion in the current episode, whereas the frequency of
episodes per year is negatively correlated with persis-
tence. The use of antidepressants and hypnotic
medications in the 6 months before the episode are
negatively correlated with duration of therapy, while
mood stabilizer use is positively correlated with dura-
tion of therapy in 3 of 4 models. Duration of therapy
generally improves with age but is negatively corre-
lated with a prior psychiatric hospitalization and black
Table 1 Baseline patient characteristics by drug and type of episode
Demographics and prior use Olanzapine Risperidone Quetiapine Typicals
Restart episodes using same medication N = 40,510
(61.5%)
N = 30,469
(57.6%)
N = 10,385
(38.3%)
N = 29,422
(43.8%)
Age (years) 42.5 43.5 42.0 46.3
White (%) 45.9 45.1 50.0 45.2
Male (%) 55.0 48.7 46.2 50.3
Disabled (%) 75.6 74.4 74.3 84.1
Health-care cost ($/prior 6 months) 6,674 6,677 7,930 5,454
Days off antipsychotic therapy 73 72 56 99
Delayed switching episodes N = 11,459
(17.4%)
N = 9,483
(17.9%)
N = 6,407
(23.6%)
N = 11,176
(16.6%)
Age (years) 42.6 42.8 41.8 42.7
White (%) 47.7 46.7 48.7 46.7
Male (%) 54.2 50.1 50.1 51.7
Disabled (%) 77.3 75.6 75.6 79.8
Health-care cost ($/prior 6 months) 8,328 8,315 8,355 9,631
Days off antipsychotic therapy 314 305 240 236
Switching episodes N = 7,694
(11.7%)
N = 6,761
(12.8%)
N = 5,258
(19.4%)
N = 7,055
(10.5%)
Age (years) 43.1 43.3 42.8 43.0
White (%) 52.7 52.0 54.5 51.1
Male (%) 52.5 49.8 47.9 50.6
Disabled (%) 80.2 79.7 78.1 82.2
Health-care cost ($/prior 6 months) 10,076 10,353 10,149 11,178
Augmentation episodes N = 6181
(9.4%)
N = 6148
(11.6%)
N = 5091
(18.8%)
N = 19,510
(29.0%)
Age (in years) 42.9 42.8 42.1 43.7
White (%) 53.3 53.4 54.3 56.3
Male (%) 58.2 54.5 53.9 54.7
Disabled (%) 83.2 83.6 82.4 84.1
Health-care cost ($/prior 6 months) 10,209 10,767 10,472 14,558
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race. In general, duration of therapy is positively cor-
related with the patients’ prior consumption of health-
care services as measured by the natural log of total
cost.
The results for all analyses are summarized in
Table 4 and are consistent with the unadjusted data
presented in Table 2. Patients using olanzapine, risperi-
done, or quetiapine consistently achieve better drug
therapy outcomes than patients initiating therapy
using a conventional antipsychotic. The differences
favoring the atypical antipsychotics are the smallest in
restart episodes (13–15 days on index medication; Cox
proportional HR of 0.85–0.87) and become more
clinically signiﬁcant when patients are switching medi-
cations (41–52 days; HR = 0.63–0.69) or augmenting
an existing therapy (59–65 days; HR = 0.55–0.58).
Although olanzapine consistently displays the
largest differences relative to conventional antipsy-
chotics (26 of 32 comparisons), the range of estimated
differences across the atypical antipsychotics is consis-
tently small. For example, the difference between olan-
zapine and its competitors in terms of duration on the
index therapy ranges from a low of 2 days for restart
episodes to a high of 11 days for switching episodes.
Discussion
The differences favoring the atypical antipsychotics
reported here are consistent with clinical trial results
that document signiﬁcantly better compliance for
atypical antipsychotics when compared with conven-
tional antipsychotics. Nevertheless, the differences
favoring quetiapine and risperidone relative to typical
antipsychotics are not consistent with CATIE results
that found no differences between these drugs and
perphenazine [2].
Our results favoring olanzapine over conventional
antipsychotics are consistent with the CATIE compari-
sons of olanzapine with perphenazine [2]. The CATIE
study found a median duration of therapy using olan-
zapine of 9.2 months versus 5.6 months with per-
phenazine in a mix of restart, delayed switching, and
switching episodes. This study found the mean dura-
tion of therapy for olanzapine to vary between
4.7 months and 6.5 months, depending on episode
type, compared with 3.6 to 4.3 months for conven-
tional antipsychotics (see Table 2). Moreover, the esti-
mated Cox proportional HR for olanzapine relative to
conventional antipsychotics ranged between 0.63 and
0.85 and are consistent with CATIE results using a mix
of restart, delayed switching, and switching episodes
(HR = 0.78).
The results for switching episodes can be compared
with phase II of CATIE in which patients switching
away from their initial antipsychotic were randomly
assigned to olanzapine, risperidone, quetiapine, or
ziprasidone [3,4]. The CATIE results indicate that
time-to-discontinuation was longer for risperidone
Table 2 Unadjusted medication use patterns by drug and type of episode
Medication use pattern Olanzapine Risperidone Quetiapine
Typical
antipsychotics
Restart episodes using same medication N = 40,510 N = 30,469 N = 10,385 N = 29,422
Days of therapy: initial drug 142
(4.7 months)
139
(4.6 months)
135
(4.5 months)
128
(4.3 months)
Days of therapy: all drugs 157 155 156 154
Switch/augment (%) 12.58 12.38 19.11 15.11
Time to switch/augment 148 144 125 147
No. of additional APs in ﬁrst year 2.13 2.15 2.41 2.43
Delayed switching episodes N = 11,459 N = 9,483 N = 6,407 N = 11,176
Days of therapy: initial drug 143
(4.8 months)
135
(4.5 months)
127
(4.2 months)
108
(3.6 months)
Days of therapy: all drugs 177 170 166 159
Switch/augment (%) 26.93 27.23 31.14 33.94
Time to switch/augment 125 118 109 103
No. of additional APs in ﬁrst year 2.46 2.41 2.70 2.91
Switching episodes N = 7,694 N = 6,761 N = 5,258 N = 7,055
Days of therapy: initial drug 195
(6.5 months)
187
(6.2 months)
166
(5.5 months)
123
(4.1 months)
Days of therapy: all drugs 266 265 248 235
Switch/augment (%) 38.06 39.15 41.52 48.70
Time to switch/augment 65 64 68 47
No. of additional APs in ﬁrst year 2.70 2.66 2.89 3.59
Augmentation episodes N = 6,181 N = 6,148 N = 5,091 N = 19,510
Days of therapy: initial drug 186
(6.2 months)
179
(6.0 months)
162
(5.4 months)
90
(3.0 months)
Days of therapy: all drugs 363 364 343 377
Switch/augment (%) 39.82 41.23 41.64 51.14
Time to switch/augment 106 105 102 84
No. of additional APs in ﬁrst year 2.64 2.62 2.79 3.29
AP, antipsychotics.
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(7.0 months) than for olanzapine (6.3 months), al-
though the HR for the likelihood of discontinuation
did not conﬁrm these unadjusted comparisons (HR =
1.02, 95% CI 0.67–1.55). Patients who switched to
quetiapine achieved a median duration of 4.0 months,
which was statistically shorter than for olanzapine or
risperidone. Our results for duration were: risperidone
6.2 months; olanzapine 6.5 months; and quetiapine
5.5 months, with the difference between olanzapine
and risperidone not achieving statistical signiﬁcance.
Our results favoring atypical antipsychotics in
general, and olanzapine in particular, are also consis-
tent with previous studies using either retrospective
paid claims data [7–10] or data from prospective trials
designed to more closely approximate real-world clini-
cal practice [11,12]., These previous studies, however,
found larger differences between olanzapine and ris-
peridone than reported here: 13 days in Indiana Med-
icaid [10]; 22 days in the US-SCAP study [11]; 29 days
in Ramsey et al. [9]; 37 days in Texas Medicaid; and
44 days (unadjusted) in Michigan Medicaid [8]. These
studies do not fully document the patient’s prior use
of nonstudy antipsychotic drugs and may therefore
include a mix of long and short duration episode
Table 3 Ordinary least squares models of duration of therapy using the index medication
Independent variables
Episode type
Restart
N = 106,728
(46,836
patients)
Delayed switch
N = 32,443
(24,105
patients)
Switching
N = 26,024
(17,538
patients)
Augmentation
N = 35,352
(19,959
patients)
Index drug (vs. typical antipsychotics)
Olanzapine 14.54* 36.17* 52.42* 65.40*
Risperidone 12.76* 31.45* 45.84* 62.91*
Quetiapine 13.67* 28.14* 41.42* 58.56
Antipsychotic drug use history
Change class of drugs -2.18† 4.58‡ 3.01 6.24*
Combination therapy on index date — 17.40* 2.96 -5.12
Time off antipsychotic therapy -0.02* 0.002 NA NA
Duration of previous episode (in days) 0.11* 0.07* NA NA
Prior episodes per year -3.55* -1.52* -0.12‡ -0.12‡
Prior psychotropic drug use
Antidepressants -2.03‡ -3.10† -8.06* -9.19*
Mood stabilizers 2.96‡ 9.55* 6.30* -1.27
Depot antipsychotic drug 0.58 9.42* 0.10 -9.96*
Drugs for extrapyramidal symptoms 4.60 17.11‡ -9.33 21.14*
Hypnotics -7.97* -3.15 -9.50‡ -4.03
Anticonvulsants 2.22† -3.50† 0.78 -7.14*
Age (<25 as comparison group)
Age 25–35 -0.78 2.42 -2.20 1.89
Age 35–45 -0.05 4.25 1.99 7.57‡
Age 45–55 2.86† 6.96‡ 4.52 9.87*
Age 55–65 6.50* 12.02* 14.54* 10.39‡
Age 65+ 9.78* 20.64* 15.91* 2.17
Race (vs. white)
Hispanic -0.73 -3.49 -3.43 -4.56
Black -11.92* -14.62* -14.16* -8.07*
Asian 3.98† 4.07 8.18 -4.16
Other/unknown -4.00* -4.28‡ -5.25‡ -2.39
Male 2.25‡ 0.93 4.74§ 6.87*
Prior use of health care (6 months)
Acute hospital use -3.11 -6.39‡ -5.05 -4.72
Psychiatric hospital use -9.65* -7.11* -14.07* -16.71*
Nursing home use 12.06* 13.28* 4.91 -22.28*
LOGe (Total cost) 4.23* 4.86* 6.16* 3.14*
Diagnostic proﬁle (prior 6 months)
Infectious diseases -6.75‡ -6.90‡ 12.40† 9.22
Human immunodeﬁciency virus -23.42‡ -18.87‡ -41.71‡ -20.31
Skin disorders 5.34* 3.82† 12.22* 6.50*
Muscle disorders -4.39‡ -4.78‡ -4.82‡ -3.21†
Trauma (nonaccident-related) -4.83* -6.46* -8.12* -6.94*
Hyperlipidemia 3.98‡ 1.65 10.09* 7.63*
Schizophrenia 7.05‡ 3.35‡ 3.24 5.93*
Anxiety -4.70‡ -5.48‡ -12.25* -8.97*
Depression -1.03 -4.17† -8.05‡ -7.58‡
Bipolar disorders -1.41 -6.83* -8.76* -8.30*
Substance abuse -10.97* -10.91* -14.72* -9.51*
Dementia 16.88* 30.69* 45.73* 25.10*
Digestive disorders -0.92 -3.41† -5.79§ -3.59†
*P < 0.0001; †P < 0.05; ‡P < 0.01.
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types that are not equally distributed across the study
drugs.
Limitations
Analyses based on paid claims data have a host of
limitations that must be considered in interpreting
their results. First, clinical data documenting potential
differences in severity of illness and sensitivity to side
effects across alternative drugs are not available on
paid claims. Second, patients may not maintain con-
tinuous Medi-Cal eligibility or may receive care from
other sources of coverage, such as the VA or county
health facilities. However, most of the sample
included in this study gained Medi-Cal eligibility
because of disability status, thus reducing the likeli-
hood of losing eligibility but increasing the likelihood
of receiving care outside the Medi-Cal system. These
Table 4 Estimated impact of atypical antipsychotics (APs) compared with conventional medications on antipsychotic medication use
patterns
Olanzapine Risperidone Quetiapine
Combo
therapy
Changed
class
Goodness of
ﬁt statistics
Restart episodes using same medication:
N = 106,728* (46,836 individual patients)
Logistic odds ratios Pseudo R2
Terminated index AP 0.71† 0.73† 0.72† NA 1.01 0.1176
Terminated all APs 0.90‡ 0.89‡ 0.82† NA 0.88† 0.1218
Switch/augment 0.76† 0.77† 1.15† NA 2.10† 0.0622
Days of therapy Adjusted R2
Duration-index AP 15† 13† 14† NA -2§ 0.1545
Duration-all APs 9† 8† 12† NA 5† 0.1604
Cox hazard ratios
Time to quit: index AP 0.85† 0.87† 0.85† NA 1.01
Time to quit: all APs 0.92† 0.92† 0.88† NA 0.95†
Time to switch/augment 0.68† 0.70† 0.97 NA 1.97†
Delayed switching episodes: N = 32,443*
(24,105 individual patients)
Logistic odds ratios Pseudo R2
Terminated index AP 0.45† 0.52† 0.61† 0.80† 0.77† 0.1197
Terminated all APs 0.71† 0.75† 0.77† 0.73† 0.82† 0.1116
Switch/augment 0.73† 0.77† 0.91‡ 1.43† 1.08‡ 0.0495
Days of therapy Adjusted R2
Duration-index AP 36† 31† 28† 17† 5‡ 0.1285
Duration-all APs 23† 21† 20† 20† 6† 0.1299
Cox hazard ratios
Time to quit: index AP 0.67† 0.71† 0.72† 0.88† 0.95†
Time to quit: all APs 0.81† 0.83† 0.82† 0.86† 0.95†
Time to switch/augment 0.58† 0.61† 0.71† 1.11† 1.05
Switching episodes: N = 26,024*
(17,538 individual patients)
Logistic odds ratios Pseudo R2
Terminated index AP 0.35† 0.38† 0.44† 1.17 0.94 0.1146
Terminated all APs 0.70† 0.70† 0.75† 0.86 0.85† 0.1019
Switch/augment 0.70† 0.77† 0.86† 1.45† 1.33† 0.0474
Days of therapy Adjusted R2
Duration-index AP 52† 46† 41† 3 3 0.1031
Duration-all APs 28† 27† 26† 13‡ 10† 0.1041
Cox hazard ratios
Time to quit: index AP 0.63† 0.66† 0.69† 0.95 0.98‡
Time to quit: all APs 0.84† 0.85† 0.85† 0.87† 0.92†
Time to switch/augment 0.60† 0.65† 0.70† 1.18† 1.28†
Augmentation episodes: N = 36,352*
(19,959 individual patients)
Logistic odds ratios Pseudo R2
Terminated index AP 0.31† 0.33† 0.38† 1.09 0.91§ 0.1114
Terminated all APs 0.97 0.91‡ 0.95 0.95 0.86† 0.1232
Switch/augment 0.74† 0.81† 0.85† 1.50† 1.29† 0.0665
Days of therapy Adjusted R2
Duration-index AP 65† 63† 59† -5 6† 0.1143
Duration-all APs 3 5§ 6§ -1 10† 0.1399
Cox hazard ratios
Time to quit: index AP 0.55† 0.56† 0.58† 0.97 0.95†
Time to quit: all APs 0.97 0.95‡ 0.95§ 0.98 0.92†
Time to switch/augment 0.76† 0.81† 0.84† 1.32† 1.19†
*Small reductions in the sample included in the multivariate analyses were caused by missing values in one or more of the independent variables used in the models.
†P < 0.001; ‡P < 0.01; §P < 0.05.
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losses in a patient’s paid claims history could bias
study results if lost eligibility or out-of-system use is
not equally distributed across the alternative drugs
under study.
Using the gap of 15 days selected by the Medi-Cal
program to deﬁne discontinuation of drug therapy can
be debated. For restart episodes, which constitute
nearly half of all treatment episodes, substituting an
alternative gap of 30 days would collapse sequential
restart episodes separated by 16 to 30 days into a
single episode and increase the average duration of
therapy. This change would favor the atypical antipsy-
chotics in general, which have a smaller average gap
(56–73 days, Table 1) relative to conventional antipsy-
chotics (99 days). Moreover, changing to a 30-day gap
would favor olanzapine and risperidone in particular
given that these drugs are used predominately in
restart episodes. Increasing the gap used to deﬁne dis-
continuation of therapy would have little effect on
delayed switching episodes, which are separated by
average gaps ranging between 236 days (typicals) and
315 days (olanzapine).
Source of ﬁnancial support: This research was funded by a
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